These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Unusual Increased Blood Pool Activity on 68Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease. Sharma A; Navaz AJ; Pandey MK; Parent EE Clin Nucl Med; 2022 Feb; 47(2):137-139. PubMed ID: 34690295 [TBL] [Abstract][Full Text] [Related]
24. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor. Chan M; Schembri GP Clin Nucl Med; 2017 Feb; 42(2):108-109. PubMed ID: 27997429 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic and Therapeutic Uptake of Intrathyroid Metastasis of Midgut Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE Imaging. Vija Racaru L; Sinigaglia M; Fontaine S; DʼAure D; Courbon F; Dierickx L Clin Nucl Med; 2019 Jul; 44(7):e445-e448. PubMed ID: 31021912 [TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT Findings in a Patient With Primary Renal Well-Differentiated Neuroendocrine Tumor. Şahin R; Baykal Koca S; Yücetaş U; Çermik TF; Ergül N Clin Nucl Med; 2022 Jul; 47(7):e503-e505. PubMed ID: 35384913 [TBL] [Abstract][Full Text] [Related]
27. A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice. Aalbersberg EA; Geluk-Jonker MM; Young-Mylvaganan T; de Wit-van der Veen LJ; Stokkel MPM J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058910 [TBL] [Abstract][Full Text] [Related]
28. 68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis? Jackson T; Darwish M; Cho E; Nagatomo K; Osman H; Jeyarajah DR Abdom Radiol (NY); 2021 Jul; 46(7):3179-3183. PubMed ID: 33665733 [TBL] [Abstract][Full Text] [Related]
30. Imaging Characteristics of Coexisting Primary Pulmonary Carcinoid Tumor and Multiple Myeloma on 18F-FDG and 68Ga-DOTATATE PET/CT. Lu Y Clin Nucl Med; 2019 Nov; 44(11):914-915. PubMed ID: 31306189 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446 [TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865 [TBL] [Abstract][Full Text] [Related]
33. Concomitant Pancreatitis and Pancreatic Neuroendocrine Tumor on MRI and 68 Ga-DOTATATE PET/CT. Wang J; Kuker R Clin Nucl Med; 2024 Sep; 49(9):868-872. PubMed ID: 38758529 [TBL] [Abstract][Full Text] [Related]
34. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of Adnan A; Basu S J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476 [TBL] [Abstract][Full Text] [Related]
35. Standardized uptake values and ratios on 68Ga-DOTATATE PET-computed tomography for normal organs and malignant lesions and their correlation with Krenning score in patients with metastatic neuroendocrine tumors. Menon BK; Kalshetty A; Bhattacharjee A; Basu S Nucl Med Commun; 2020 Oct; 41(10):1095-1099. PubMed ID: 32732598 [TBL] [Abstract][Full Text] [Related]
37. Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient. Jullien M; Reichert T; D'Anella P; Castinetti F; Barlier A; Brue T; Taieb D; Cuny T Ann Endocrinol (Paris); 2020 Feb; 81(1):39-43. PubMed ID: 31982106 [TBL] [Abstract][Full Text] [Related]
39. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. You H; Kandathil A; Beg M; De Blanche L; Kazmi S; Subramaniam RM Nucl Med Commun; 2020 Oct; 41(10):1060-1065. PubMed ID: 32732600 [TBL] [Abstract][Full Text] [Related]
40. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management. Kunikowska J; Lewington V; Krolicki L Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]